Role of 11C-Methionine PET/CT in 99mTc-Sestamibi-Negative Parathyroid Adenoma: A Case Report
Department of Nuclear medicine, VHS Medical Center, Seoul 05368, Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2021, 11(5), 831; https://doi.org/10.3390/diagnostics11050831
Submission received: 7 April 2021
/
Revised: 26 April 2021
/
Accepted: 3 May 2021
/
Published: 4 May 2021
(This article belongs to the Collection Interesting Images)
Abstract
:We report a case of 16-year-old female primary hyperparathyroidism patient who underwent cervical ultrasonography and 99mTc-sestamibi single photon emission computed tomography/computed tomography, both of which were negative for parathyroid adenoma. Subsequent 11C-methionine positron emission tomography/CT showed positive focal uptake suggesting parathyroid adenoma, which then was confirmed pathologically.
Primary hyperparathyroidism (pHPT) is a common endocrine disorder characterized by elevated parathyroid hormone and serum calcium level caused by one or more parathyroid adenomas, parathyroid hyperplasia, or in rare cases, by parathyroid carcinoma [1] (Figure 1). Surgical resection of parathyroid adenoma or hyperplastic parathyroid glands is the curative treatment for pHPT patients. Various imaging modalities are required to avoid extensive surgery and establish a more targeted surgical approach. Preoperative imaging modalities include cervical ultrasonography (US); 99mTc-sestamibi scintigraphy, which has been recently combined with single photon emission computed tomography/computed tomography (SPECT/CT) (Figure 2); and 11C-methionine positron emission tomography/CT (11C-MET PET/CT) (Figure 3) [2,3,4,5,6,7].
False negative findings of 99mTc-sestamibi scintigraphy can occur due to various reasons. The most common is parathyroid ademona of small size, which allows limited spatial resolution of conventional scintigraphic techiniques [8]. Other reasons for false negative findings are lack of oxyphil cells, parathyroid hyperplasia, multiglandular disease, and high expression of P-glycoprotein [9,10]. In our institute, subsequent 11C-MET PET/CT is performed in patients with laboratory findings highly suggestive of pHPT and negative or inconclusive results of US and 99mTc-sestamibi SPECT/CT because the higher resolution of PET/CT could improve localization of small lesions.11C-MET is a PET radiopharmaceutical agent that is trapped in the hyperfunctioning parathyroid gland during synthesis of the PTH precursor [11]. The major limitation of this agent is the short physical half-life of 11C (20.3 min). To overcome this limitation, an on-site cyclotron is necessary, an instrument that is not available in most clinics.
Author Contributions
J.Y.: involved in initial drafting of manuscript. M.C.: involved in review of the images. All authors have read and agreed to the published version of the manuscript.
Funding
This report received no external funding.
Institutional Review Board Statement
This study was conducted according to the guidelines of the Declaration of Helsinki, and ethical review and approval were waived for the single case report.
Informed Consent Statement
Written informed consent for publication was obtained from the parents of the patient involved in the study.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Sitges-Serra, A.; Bergenfelz, A. Clinical update: Sporadic primary hyperparathyroidism. Lancet 2007, 370, 468–470. [Google Scholar] [PubMed]
- Braeuning, U.; Pfannenberg, C.; Gallwitz, B.; Teichmann, R.; Mueller, M.; Dittmann, H.; Reimold, M.; Bares, R. 11C-methionine PET/CT after inconclusive 99mTc-MIBI-SPECT/CT for localisation of parathyroid adenomas in primary hyperparathyroidism. Nuklearmedizin 2015, 54, 26–30. [Google Scholar] [CrossRef] [PubMed]
- Noltes, M.E.; Coester, A.M.; van der Horst-Schrivers, A.N.; Dorgelo, B.; Jansen, L.; Noordzij, W.; Lemstra, C.; Brouwers, A.H.; Kruijff, S. Localization of parathyroid adenomas using 11C-methionine PET after prior inconclusive imaging. Langenbecks Arch. Surg. 2017, 402, 1109–1117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lenschow, C.; Gassmann, P.; Wenning, C.; Senninger, N.; Colombo-Benkmann, M. Preoperative 11C-Methionine PET/CT enables focused parathyroidectomy in MIBI-SPECT negative parathyroid adenoma. World J. Surg. 2015, 37, 1750–1757. [Google Scholar] [CrossRef] [PubMed]
- Traub-Weidinger, T.; Mayerhoefer, M.E.; Koperek, O.; Mitterhauser, M.; Duan, H.; Karanikas, G.; Niederle, B.; Hoffmann, M. 11C-methionine PET/CT imaging of 99mTc-MIBI-SPECT/CT-negative patients with primary hyperparathyroidism and previous neck surgery. J. Clin. Endocrinol. Metab. 2014, 99, 4199–4205. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yuan, L.; Liu, J.; Kan, Y.; Yang, J.; Wang, X. The diagnostic value of 11C-methionine PET in hyperparathyroidism with negative 99mTc-MIBI SPECT: A meta-analysis. Acta Radiol. 2017, 58, 558–564. [Google Scholar] [PubMed]
- Ovčariček, P.P.; Giovanella, L.; Gasset, I.C.; Hindié, E.; Huellner, M.W.; Luster, M.; Piccardo, A.; Weber, T.; Talbot, J.-N.; Verburg, F.A. The EANM practice guidelines for parathyroid imaging. Eur. J. Nucl. Med. Mol. Imaging 2021, 1–22. [Google Scholar] [CrossRef]
- Piciucchi, S.; Barone, D.; Gavelli, G.; Dubini, A.; Oboldi, D.; Matteuci, F. Primary hyperparathyroidism: Imaging to pathology. J. Clin. Imaging Sci. 2012, 2, 59. [Google Scholar] [CrossRef] [PubMed]
- Melloul, M.; Paz, A.; Koren, R.; Cytron, S.; Feinmesser, R.; Gal, R. 99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance. Eur. J. Nucl. Med. 2001, 28, 209–213. [Google Scholar] [CrossRef] [PubMed]
- Eslamy, H.K.; Ziessman, H.A. Parathyroid scintigraphy in patients with primary hyperparathroidism: 99mTc Sestamibi SPECT and SPECT/CT. Radiographics 2008, 28, 1461–1476. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Otto, D.; Boemer, A.R.; Hofmann, M.; Brunkhorst, T.; Meyer, G.J.; Petrich, T.; Scheumann, G.F.; Knapp, W.H. Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1405–1412. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
A 16-year-old female patient with elevated parathyroid hormone and serum calcium levels (89.6 pg/mL and 12.8 mg/dL, respectively) underwent initial neck ultrasonography (US) ((A) right; (B) left) for parathyroid gland evaluation. The images showed heterogeneous echotexture thyroid parenchyme and multiple hypoechoic nodules in both glands but no demonstrable evidence of parathyroid adenoma.
Figure 1.
A 16-year-old female patient with elevated parathyroid hormone and serum calcium levels (89.6 pg/mL and 12.8 mg/dL, respectively) underwent initial neck ultrasonography (US) ((A) right; (B) left) for parathyroid gland evaluation. The images showed heterogeneous echotexture thyroid parenchyme and multiple hypoechoic nodules in both glands but no demonstrable evidence of parathyroid adenoma.
Figure 2.
Subsequently, a 99mTc-sestamibi scan was performed at 20 min (A) and 150 min (B) after radiopharmaceutical injection. There was no abnormal remaining radiotracer uptake lesion suggestive of parathyroid adenoma. Subsequent single photon emission computed tomography/computed tomography (SPECT/CT) (C) did not provide additional evidence of parathyroid adenoma.
Figure 2.
Subsequently, a 99mTc-sestamibi scan was performed at 20 min (A) and 150 min (B) after radiopharmaceutical injection. There was no abnormal remaining radiotracer uptake lesion suggestive of parathyroid adenoma. Subsequent single photon emission computed tomography/computed tomography (SPECT/CT) (C) did not provide additional evidence of parathyroid adenoma.
Figure 3.
11C-Methionine positron emission tomography/CT (11C-MET PET/CT) (A) PET image; (B) CT image; (C) fusion PET/CT image) was performed for primary site localization of primary hyperparathyroidism (pHPT) and showed a small lesion in the posterior aspect of the right thyroid gland (arrow). Right parathyroidectomy was performed and pathologically indicated a 0.8-cm-sized parathyroid adenoma. Since the operation, both parathyroid hormone and serum calcium levels have normalized (31.4 pg/mL and 9.8 mg/dL, respectively).
Figure 3.
11C-Methionine positron emission tomography/CT (11C-MET PET/CT) (A) PET image; (B) CT image; (C) fusion PET/CT image) was performed for primary site localization of primary hyperparathyroidism (pHPT) and showed a small lesion in the posterior aspect of the right thyroid gland (arrow). Right parathyroidectomy was performed and pathologically indicated a 0.8-cm-sized parathyroid adenoma. Since the operation, both parathyroid hormone and serum calcium levels have normalized (31.4 pg/mL and 9.8 mg/dL, respectively).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Yoo, J.; Cheon, M. Role of 11C-Methionine PET/CT in 99mTc-Sestamibi-Negative Parathyroid Adenoma: A Case Report. Diagnostics 2021, 11, 831. https://doi.org/10.3390/diagnostics11050831
AMA Style
Yoo J, Cheon M. Role of 11C-Methionine PET/CT in 99mTc-Sestamibi-Negative Parathyroid Adenoma: A Case Report. Diagnostics. 2021; 11(5):831. https://doi.org/10.3390/diagnostics11050831
Chicago/Turabian StyleYoo, Jang, and Miju Cheon. 2021. "Role of 11C-Methionine PET/CT in 99mTc-Sestamibi-Negative Parathyroid Adenoma: A Case Report" Diagnostics 11, no. 5: 831. https://doi.org/10.3390/diagnostics11050831
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
